3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Renal Cell
38
Kidney Neoplasms
20
Melanoma
14
Neoplasm Metastasis
13
Prostatic Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Lymphoma
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Vaginal Neoplasms
1
Turcot syndrome
1
Skin Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Multiple Myeloma
1
Microsatellite Instability
1
Mesothelioma, Malignant
1
Interventions
pembrolizumab
21
Nivolumab
7
Docetaxel
7
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Trastuzumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
atezolizumab
3
Taxes
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorouracil
3
Counseling
3
Cisplatin
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
poly ICLC
2
durvalumab
2
belinostat
2
X-Rays
2
Standard of Care
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Interleukin-2
×
Genitourinary
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled